[Long-term management after myocardial infarction (Part 2.): Medical interventions].
Czuriga
István
I
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Atalános Orvostudományi Kar, Kardiológiai Intézet. iczuriga@jaguar.dote.hu
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D000925:Anticoagulants / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D003663:Decision Trees; D004334:Drug Administration Schedule; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000534:rehabilitation*; D005996:Nitroglycerin / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D005996:Nitroglycerin; D001241:Aspirin